Page 42 - Read Online

Page 10 of 11 Gasparello et al. J Cancer Metastasis Treat 2019;5:52 I http://dx.doi.org/10.20517/2394-4722.2019.17

prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010;25:1674-80.
38. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of
colorectal cancer. Tumour Biol 2013;34:2175-81.
39. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, et al. Circulating plasma MiR- 141 is a novel biomarker for metastatic colon
cancer and predicts poor prognosis. PLoS One 2011;6:e17745.
40. Lv ZC, Fan YS, Chen HB, Zhao DW. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal
cancer. Tumour Biol 2015;36:1619-25.
41. Krawczyk P, Powrózek T, Olesiński T, Dmitruk A, Dziwota J, et al. Evaluation of miR-506 and miR-4316 expression in early and non-
invasive diagnosis of colorectal cancer. Int J Colorectal Dis 2017;32:1057-60.
42. Liu C, Eng C, Shen J, Lu Y, Takata Y, et al. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon
cancer. Oncotarget 2016;7:76250-60.
43. Li N, Ma J, Guarnera MA, Fang H, Cai L, et al. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer
Res Clin Oncol 2014;140:145-50.
44. Leng Q, Lin Y, Jiang F, Lee CJ, Zhan M, et al. A plasma miRNA signature for lung cancer early detection. Oncotarget 2017;8:111902-11.
45. Margue C, Reinsbach S, Philippidou D, Beaume N, Walters C, et al. Comparison of a healthy miRNome with melanoma patient
miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget 2015;6:12110-27.
46. Müllauer L. Next generation sequencing: clinical applications in solid tumours. Memo 2017;10:244-7.
47. Giuffrida MC, Zanoli LM, D'Agata R, Finotti A, Gambari R, et al. Isothermal circular- strand-displacement polymerization of DNA and
microRNA in digital microfluidic devices. Anal Bioanal Chem 2015;407:1533-43.
48. Guo Q, Yang X, Wang K, Tan W, Li W, et al. Sensitive fluorescence detection of nucleic acids based on isothermal circular strand-
displacement polymerization reaction. Nucleic Acids Res 2009;37:e20.
49. D'Agata R, Breveglieri G, Zanoli LM, Borgatti M, Spoto G, et al. Direct detection of point mutations in nonamplified human genomic
DNA. Anal Chem 2011;83:8711-7.
50. Bellassai N, Spoto G. Biosensors for liquid biopsy: circulating nucleic acids to diagnose and treat cancer. Anal Bioanal Chem
2016;408:7255-64.
51. Finotti A, Allegretti M, Gasparello J, Giacomini P, Spandidos DA, et al. Liquid biopsy and PCR-free ultrasensitive detection systems in
oncology. Int J Oncol 2018;53:1395-1434.
52. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
53. Hu Z, Chen X, Zhao Y, Tian T, Jin G, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression
profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-6.
54. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, et al. Discovery of circulating microRNAs associated with human prostate cancer
using a mouse model of disease. Int J Cancer 2012;131:652-61.
55. Gasparello J, Allegretti M, Tremante E, Fabbri E, Amoreo CA, et al. Liquid biopsy in mice bearing colorectal carcinoma xenografts:
gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). J Exp Clin Cancer Res 2018;37:124.
56. Greystoke A, Ayub M, Rothwell DG, Morris D, Burt D, et al. Development of a circulating miRNA assay to monitor tumor burden:
From mouse to man. Mol Oncol 2016;10:282-91.
57. Chapin SC, Doyle PS. Ultrasensitive multiplexed microRNA quantification on encoded gel microparticles using rolling circle
amplification. Anal Chem 2011;83:7179-85.
58. Williams MR, Stedtfeld RD, Stedtfeld TM, Tiedje JM, Hashsham SA. Quantification of microRNAs directly from body fluids using a
base-stacking isothermal amplification method in a point-of-care device. Biomed Microdevices 2017;19:45.
59. Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S, et al. Sensitive and specific detection of microRNAs by northern blot analysis
using LNA-modified oligonucleotide probes. Nucleic Acids Res 2004;32:e175.
60. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. MicroRNA expression profiles classify human cancers. Nature
2005;435:834-8.
61. Garcia-Olmo DC, Gutierrez-Gonzalez L, Ruiz-Piqueras R, Picazo MG, Garcia-Olmo D. Detection of circulating tumor cells and of
tumor DNA in plasma during tumor progression in rats. Cancer Lett 2005;217:115-23.
62. Rago C, Huso DL, Diehl F, Karim B, Liu G, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA.
Cancer Res 2007;67:9364-70.
63. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, et al. Origin and quantification of circulating DNA in mice with human
colorectal cancer xenografts. Nucleic Acids Res 2010;38:6159-75
64. Goodale D, Phay C, Postenka CO, Keeney M, Allan AL. Characterization of tumor cell dissemination patterns in preclinical models of
cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry A 2009;75A:344-55.
65. Fan ZC, Yan J, Liu GD, Tan XY, Weng XF, et al. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic
model by in vivo flow cytometry assesses resection on metastasis. Cancer Res 2012;72:2683-91.
66. Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997;15:272-306.
67. Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer
medicine. EMBO Mol Med 2017;9:137-53.
68. Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat Rev
Cancer 2017;17:751-65.